Provectus Biopharmaceuticals

Focus: Provectus Biopharmaceuticals is a small molecule oncology-focused company headquartered in Knoxville, Tennessee, with a pipeline centered on PV-10, a therapeutic agent for cutaneous and metastatic tumors.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Provectus Biopharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Provectus Biopharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

PV-10

Cutaneous or Subcutaneous Tumors Where There is no Comparable or Satisfactory

N/A

Clinical Trials (1)

NCT01260779Expanded Access Protocol for PV-10 for Cutaneous or Subcutaneous Tumors

N/A

Help build intelligence for Provectus Biopharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Lead a focused pipeline with PV-10 in Phase 3 for cutaneous melanoma, representing a clear near-term value inflection point
Work on oncology programs with multi-indication potential across melanoma, liver metastases, and neuroendocrine tumors
Join a lean, specialized organization where individual contributions directly impact drug development trajectory

Watch Out For

No active job openings and minimal hiring activity signals organizational contraction or pause in growth
Pre-revenue stage with undisclosed funding and financials creates uncertainty around runway and cash stability
Limited public disclosure on employee count, stage, and financial position restricts visibility into company health

Generated by Claude from Provectus Biopharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Rose bengal disodium

Neuroendocrine Tumors Metastatic to the Liver

Phase 1

Clinical Trials (1)

NCT02693067A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver

Phase 1

PV-10

Cancer Metastatic to the Liver

Phase 1

Clinical Trials (1)

NCT00986661A Study to Assess PV-10 Chemoablation of Cancer of the Liver

Phase 1